RxDoctor Payments Data

Shaun McMurtry, MD

Family Medicine · McKinney, TXNPI 1093910697

Payments from drug & device makers

$1,729in general payments, 2019–2025

Across 96 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$268
  • Bayer$204
  • AstraZeneca$200
  • GSK$195
  • Lilly USA, LLC$182
  • Pfizer$114
  • plus $566 from 12 others

What the payments were for

  • Food & beverage$1,71799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,729 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$85,445
Medicare patients
254
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide86$134,293
OzempicSemaglutide46$80,971
JardianceEmpagliflozin43$57,139
JanuviaSitagliptin Phosphate35$42,105
EliquisApixaban35$37,542
XareltoRivaroxaban11$15,365
Tresiba Flextouch U-100Insulin Degludec18$15,000
KerendiaFinerenone13$11,639
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$7,000
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,520
SymbicortBudesonide/Formoterol Fumarate11$4,617
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$4,586
Atorvastatin Calcium433$3,731
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,508
Insulin Lispro Kwikpen U-100Insulin Lispro12$3,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$182$134,29386 claims
Novo NordiskOzempic$268$80,97146 claims
Boehringer IngelheimJardiance, Stiolto Respimat$85$62,65955 claims
MerckJanuvia$84$42,10535 claims
PfizerEliquis$114$37,54235 claims
BayerKerendia$204$11,63913 claims
AstraZenecaSymbicort$200$4,61711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →